To Evaluate Safety and Efficacy of GS-9857 Plus Sofosbuvir/velpatasvir Fixed Dose Combination in Patients With Chronic Genotype 1 HCV Infection with and Without Cirrhosis

Trial Profile

To Evaluate Safety and Efficacy of GS-9857 Plus Sofosbuvir/velpatasvir Fixed Dose Combination in Patients With Chronic Genotype 1 HCV Infection with and Without Cirrhosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Aug 2015

At a glance

  • Drugs GS 9857 (Primary) ; Sofosbuvir/velpatasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top